在早期乳腺癌中,达托帕马布-德鲁克斯坦加杜尔瓦卢马布:顺序多重分配随机I-SPY2.2第二阶段试验
Rebecca A Shatsky1, Meghna S Trivedi2, Christina Yau3
1University of California San Diego, San Diego, CA, USA.
Nature medicine
|September 14, 2024
概括
与杜尔瓦卢马布 (durvalumab) 结合的达托帕马布-德鲁克斯泰干 (Dato-DXd) 在治疗高风险乳腺癌方面表现有前途. 这种新型疗法可能会替代许多患者的标准化疗,特别是那些免疫阳性亚型患者.
科学领域:
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
- 临床试验设计 临床试验设计
背景情况:
- 顺序适应性试验设计对于瘤学个性化医学至关重要.
- 优化治疗策略可以改善患者的治疗结果,并最大限度地降低毒性.
研究的目的:
- 为了评估datopotamab-deruxtecan (Dato-DXd) 与durvalumab结合作为第二阶段新辅助乳腺癌试验的初始疗法.
- 在I-SPY2.2适应性试验框架内,评估这种组合在高风险阶段2/3乳腺癌患者的疗效和安全性.
主要方法:
- I-SPY2.2试验采用了一种序列适应性设计,有三个治疗块 (A,B,C).
- 患者在A块中接受了Dato-DXd/durvalumab,随后是针对亚型的定制疗程.
- 治疗重定向以成像和活检数据为指导,早期手术切除是可选的.
主要成果:
- 达托帕马布-德鲁克斯坦/杜尔瓦卢马布在A区块后的免疫阳性亚型中超过了成功值.
- 单独使用Dato-DXd/durvalumab后,病理完整反应率为54%,A+B阻断后为92%,与标准护理相比.
- 治疗策略在荷尔蒙阴性/免疫阴性亚型中也表现出成功.
结论:
- 达托帕马布-德鲁克斯坦和杜尔瓦卢马布是高风险乳腺癌的有前途的联合疗法.
- 这种疗法有可能消除对大量患者群体的标准化疗的需要,特别是免疫阳性亚型.
- 观察到的毒性是可以控制的,口腔炎是最常见的副作用.
更多相关视频
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...


